N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study
Authors:
- Takaaki MasudaTMTakaaki Masuda
- Hiroki UeoHUHiroki Ueo
- Yuichiro KaiYKYuichiro Kai
- Miwa NodaMNMiwa Noda
- Qingjiang HuQHQingjiang Hu
- Kuniaki SatoKSKuniaki Sato
- Atsushi FujiiAFAtsushi Fujii
- Naoki HayashiNHNaoki Hayashi
- Yusuke TsurudaYTYusuke Tsuruda
- Hajime OtsuHOHajime Otsu
- Yosuke KurodaYKYosuke Kuroda
- Hidetoshi EguchiHEHidetoshi Eguchi
Open Access
- 14 January 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (2) , 511
Abstract
Background: There is growing evidence that patients with metastatic breast cancer whose disease progresses from a new metastasis (NM) have a worse prognosis than that of patients whose disease progresses from a pre-existing metastasis. The aim of this pilot study is to identify a blood biomarker predicting NM in breast cancer. Methods: The expression of epithelial (cytokeratin 18/19) or mesenchymal (plastin-3, vimentin, and N-cadherin) markers in the peripheral blood (PB) of recurrent breast cancer patients undergoing chemotherapy with eribulin or S-1 was measured over the course of treatment by RT-qPCR. The clinical significance of preoperative N-cadherin expression in the PB or tumor tissues of breast cancer patients undergoing curative surgery was assessed by RT-qPCR or using public datasets. Finally, N-cadherin expression in specific PB cell types was assessed by RT-qPCR. Results: The expression levels of the mesenchymal markers N-cadherin and vimentin were high in the NM cases, whereas that of the epithelial marker cytokeratin 18 was high in the pre-existing metastasis cases. High preoperative N-cadherin expression in PB or tumor tissues was significantly associated with poor recurrence-free survival. N-cadherin was expressed mainly in polymorphonuclear leukocytes in PB. Conclusion: N-cadherin mRNA levels in blood may serve as a novel prognostic biomarker predicting NM, including recurrence, in breast cancer patients.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP16K07177, JP16K10543, JP16K19197, JP17K16454, JP17K16521, JP17K10593, and JP17K19608)
- Oita Cancer Research Foundation (none, 15H0912, (hp170227 and hp160219, 15H05707, none, none)
- Daiwa Securities Health Foundation (none)
This publication has 42 references indexed in Scilit:
- Multiple modes of action of eribulin mesylate: Emerging data and clinical implicationsCancer Treatment Reviews, 2018
- The mode of progressive disease affects the prognosis of patients with metastatic breast cancerWorld Journal of Surgical Oncology, 2018
- Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironmentJournal of Translational Medicine, 2018
- Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus DacarbazineJournal of Clinical Oncology, 2017
- Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapyAnnals of Oncology, 2016
- “New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapyBreast Cancer Research, 2015
- Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a TaxaneJournal of Clinical Oncology, 2015
- The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 databaseEuropean Journal of Cancer, 2014
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009